A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ER / estrogen

[Related PubMed/MEDLINE]
Total Number of Papers: 834
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ER  (>> Co-occurring Abbreviation)
Long Form:   estrogen
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. AR, GR, PR, SRs
2020 AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors. AR, BC
2020 Bisphenol A-induced mechanistic impairment of decidualization. BPA, Egr-1, eNOS, NO, PR, SGK1
2020 Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer. DFS, HER2, HR, PR
2020 Effect of neoadjuvant therapy on breast cancer biomarker profile. HER2, IHC, NAT, PR
2020 Epigenetic Regulation and Dietary Control of Triple Negative Breast Cancer. HER2, PR, TNBC
2020 Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. DCIS, PgR
2020 Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells. EGF, HA, PR, rfhSP-D, SP-D
2020 Impact of Eukaryotic Translation Initiation Factors on Breast Cancer: Still Much to Investigate. BC, eIFs, PR
10  2020 Invitro profiling of the potential endocrine disrupting activities affecting steroid and aryl hydrocarbon receptors of compounds and mixtures prevalent in human drinking water resources. AhR, AR, GR, PR, TCDD
11  2020 KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature. CA125, CK5-6, CK7, EMA, PAX8, PR
12  2020 Long-term consumption of non-fermented and fermented dairy products and risk of breast cancer by estrogen receptor status - Population-based prospective cohort study. CIs, HRs, PR
13  2020 microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study. FC, miRNA, PgR
14  2020 Molecular interactions of vinclozolin metabolites with human estrogen receptors 1GWR-alpha and 1QKM and androgen receptor 2AM9-beta: Implication for endocrine disruption. AR, VCZ
15  2020 Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams. BC, GEP, HER2, IHC, PR, PT, RT, TNBC
16  2020 PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. IBC, IC, PD-L1, PDL1IC, PDL1TC, PR, TC, TILs
17  2020 Pembrolizumab and atezolizumab in triple-negative breast cancer. HER2, ICI, PD-L1, PgR, TILs, TNBC
18  2020 Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays. AhR, AR, EDCs, GR, TR
19  2020 Recurrence/Regrowth in Grade I Meningioma: How to Predict? AR, PR, TMA
20  2020 Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors. MT1, PR
21  2020 SNPs in the interleukin-12 signaling pathway are associated with breast cancer risk in Puerto Rican women. BC, IL-12, PR, SNPs
22  2020 The impact of selected risk factors among breast cancer molecular subtypes: a case-only study. BC, BI-RADS, CI, ORs, PR
23  2020 The mixture effects of bisphenol derivatives on estrogen receptor and androgen receptor. AhR, AR, BPA, BPF, BPS, BPs, EDC
24  2020 The role of histopathologic testing on apocrine carcinoma of the breast. GCDFP-15, PR
25  2019 Autism spectrum disorders, endocrine disrupting compounds, and heavy metals in amniotic fluid: a case-control study. AF, AhR, AR, ASD, EDCs, FDR, OR, PFAS, PFOS
26  2019 Clinicopathological characteristics of metaplastic breast cancer-analysis of the basic immunohistochemical profile andcomparison with other invasive breast cancer types. MpBC, PR
27  2019 Dietary Glycemic Index and Glycemic Load and Risk of Breast Cancer by Molecular Subtype in Mexican Women. BC, GI, GL, HER2, PR, TN
28  2019 Evaluation of the value of GATA3 combined with E-cadherin in the diagnosis of breast cancer. ELISA, HER2, PR
29  2019 Expression of androgen, estrogen, and progesterone hormone receptors in the penile tissues of children with different types of hypospadias. AR, PR
30  2019 HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their Association with Clinicopathologic Parameters. FISH, IC-NST, IHC, PR
31  2019 Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. IBC, PR
32  2019 Hypofractionated radiation in older women with breast cancer. IMRT, PR
33  2019 Imaging Cobalamin Uptake within Malignant Breast Tumors In Vivo. Cbl, DEX, HER2, p.i, PC, PR, SPECT, TN, WB-P
34  2019 Liraglutide treatment effects on rat ovarian and uterine tissues. CAT, FSH, GLP-1, LH, MDA, PR, SOD
35  2019 Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies. CI, HR, NHS, PR
36  2019 Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. PD, PFS, PR, QOL
37  2019 Prognostic markers in salivary gland cancer and their impact on survival. AR, DFS, EGFR, HER2, OS, PD-L1, PR, SGC, TIMC
38  2019 Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. NAT, PR
39  2019 Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas. PR
40  2019 Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience. PR, TNBC
41  2019 Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018. IHC, LI, PR
42  2019 Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo. 3'-UTRs, HER2, miRNAs, PR
43  2019 [10]-Gingerol Affects Multiple Metastatic Processes and Induces Apoptosis in MDAMB- 231 Breast Tumor Cells. HER2, PR, TNBC
44  2018 Assessment of endocrine disruption and oxidative potential of bisphenol-A, triclosan, nonylphenol, diethylhexyl phthalate, galaxolide, and carbamazepine, common contaminants of municipal biosolids. AhR, AR, BPA, DEHP, TCS, tNP, TTR
45  2018 Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. HER2, PR, TNBC
46  2018 Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. CI, MBC
47  2018 Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. PgR, uPA
48  2018 ER-/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis. DFS, IBC, OS, PR
49  2018 Estrogen and progesterone signalling in the normal breast and its implications for cancer development. PR
50  2018 Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors. AR, PR, SDC, SGTs
51  2018 Expression of hormone receptors in oropharyngeal squamous cell carcinoma. AR, HPV, OPSCC, PR
52  2018 High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice. AR, DHEA, hCG, LH, PCOS
53  2018 Identification of mitochondrial hormone receptors in avian muscle cells. GR, PR, TR
54  2018 Immunophenotypic profile of tumor buds in breast cancer. BC, HR, ngTMA, PgR
55  2018 In Vitro Tissue Microarrays for Quick and Efficient Spheroid Characterization. PR
56  2018 Incorporation of metabolic enzymes to improve predictivity of reporter gene assay results for estrogenic and anti-androgenic activity. AR
57  2018 Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups. BC, HER2, IL-7, IL-7Ralpha, PR
58  2018 Organized screening detects breast cancer at earlier stage regardless of molecular phenotype. PR
59  2018 Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers PR, PRC, TNBCs
60  2018 Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67. CI, DFS, HR, OR, PR, TMB
61  2018 PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER. PR
62  2018 Src Kinase Dependent Rapid Non-genomic Modulation of Hippocampal Spinogenesis Induced by Androgen and Estrogen. AR, DHT
63  2018 SUMOylation Regulates Transcription by the Progesterone Receptor A Isoform in a Target Gene Selective Manner. PR
64  2018 Ten-Year Survival after Liver Resection for Breast Metastases: A Single-Center Experience. PR
65  2018 Tissue Expression of Prohibition-I and It's Relationship With Prognostic Factors in Breast Cancer. IHC, PHB, PR
66  2017 Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania. MNH, MRM, PgR, SPSS, TNBC
67  2017 Clinicopathological features of patients with breast cancer aged 70 years or over. BC, DFS, HER2, LNI, LVI, OS, PgR, PNI
68  2017 Collagen concentration on the facial skin of postmenopausal women after topical treatment with estradiol and genistein: a randomized double-blind controlled trial. GEN, UNIFESP
69  2017 Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes. CBBCT, HER2, PR
70  2017 Effect of Hydrochloric Acid Decalcification on Expression Pattern of Prognostic Markers in Invasive Breast Carcinomas. BC, HCl, IHC, PR
71  2017 Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. IDC, ILC, PR
72  2017 Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer. CNB, DCIS, HER2, IBC, OR, PR
73  2017 Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables. PR, SISH
74  2017 Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences. ASCO, BCI, PAM50, PR
75  2017 Genome-wide miRNA, gene and methylation analysis of triple negative breast cancer to identify changes associated with lymph node metastases. PR, TNBC
76  2017 Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : Amonocentric clinicopathologic analysis. AR, DFS, DMFS, EGFR, LRC, PD-L1-R, PR, SDC
77  2017 Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)? DCIS, IDC, MRI, PR
78  2017 Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. CBR, EC, HR, HT, ORR, OS, PFS, PgR
79  2017 Morphological and immunohistochemical characterization of spontaneous endometriosis in rhesus macaques (Macaca mulatta). CK, IHC, PR, SMA
80  2017 Occurrence and In Vitro Bioactivity of Estrogen, Androgen, and Glucocorticoid Compounds in a Nationwide Screen of United States Stream Waters. AR, GR
81  2017 Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation. APBI, BCST, CSS, DFS, DM, IBTR, LA, LB, OS, PR
82  2017 Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro. PR, VDR
83  2017 Prognostic role of progesterone receptor expression in a population-based analysis. HER2, PR
84  2017 Prognostic value of primary tumor SUVmax on F-18 FDG PET/CT compared with semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer. ANS, BSGI, IDC, PR, pTS, TNRs
85  2017 Steroid and Xenobiotic Receptor Signalling in Apoptosis and Autophagy of the Nervous System. AhR, AR, GR, MR, PPARs, PR
86  2017 Steroid hormone receptors and direct effects of steroid hormones on ram spermatozoa. PR
87  2017 Synergistic Action of Genistein and Calcitriol in Immature Osteosarcoma MG-63 Cells by SGPL1 Up-Regulation. S1P, SGPL1, VDR
88  2017 The Impact of Androgen Receptor Expression on Endometrial Carcinoma Recurrence and Survival. AR, ECs, PR
89  2017 The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. PR
90  2017 The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. PR, TNBC
91  2017 Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients. 7NP, BLBCs, CK, DCIS, EGFR, HER2, IHC, PR, TNBCs
92  2016 An overview of the effective combination therapies for the treatment of breast cancer. BC, PR, TNBC
93  2016 Androgen receptor as potential therapeutic target in metastatic endometrial cancer. AR, PR
94  2016 Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models. BWE, MMP-3, MPA, PR
95  2016 beta-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. ---
96  2016 Case report of metastatic invasive breast lobular carcinoma to the urinary bladder. PR
97  2016 CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer. BC, HER2, PR
98  2016 Circulating Tumor Cells in Breast Cancer: Correlation with Clinicopathological Parameters, Hormone Profile and MicroRNA Polymorphisms. PR
99  2016 Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BC, CTCs, PR
100  2016 Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer. AR, CRPC, DES, PCa